New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
16:01 EDTLJPCLa Jolla announces completion of enrollment of Phase 2 study of GCS-100
La Jolla Pharmaceutical announced that it has completed enrollment of GCS-100-CS-4003, its Phase 2 Extension study of GCS-100 in chronic kidney disease. The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study. A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:02 EDTLJPCLa Jolla 4.8M share Spot Secondary priced at $10.50
The deal range was $10.40-$10.60. Jefferies acted as sole book running manager for the offering.
July 22, 2014
16:01 EDTLJPCLa Jolla files to sell common stock, no amount given
La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes. Jefferies LLC is acting as sole book-runner for the offering.
July 15, 2014
09:21 EDTLJPCOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTLJPCLa Jolla Pharma announces pre-clinical data for LJPC-1010 in NASH
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use